Sirona is pleased to announce that the second clinical trial of the active ingredient, TFC-1067, has been completed with excellent results.
VANCOUVER, BC, March 31, 2021 /CNW/ – Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona“) is pleased to announce that the second clinical trial of the active ingredient, TFC-1067, has been completed with excellent results.
The trial, which concluded on January 22nd, 2021, was managed by Dermscan (a division of Eurofins), a global leader in cosmetic clinical trials. The study’s endpoint was to determine the compound’s ability to selectively reduce areas of hyperpigmentation and dark spots of the skin while not creating a “halo” around the spot, which is a known side effect of other treatments. Multiple parameters were measured including the added effects of the higher concentration of TFC-1067 and a boosted formulation.
Results of the trial included:
- A significant decrease in spot intensity
- A significant decrease in spot size
- A significant decrease in dark spots versus surrounding skin tone
Optimal results were obtained with the higher concentration and improved formulation:
- 100% of participants agreed their complexion was illuminated
- 100% of participants agreed their complexion was brighter
- 100% of participants agreed their skin was more even in tone
- 100% of participants agreed the product blurred imperfections
- 100% of participants agreed the product prevented new dark spots from occurring
- 100% of participants agreed the spot size and mark was reduced
- 100% of participants agreed the intensity of dark spots was reduced
- 100% of participants would purchase the product
Due to contractual obligations, further disclosures will not be made at this time.
The Company also reports an increase in international interest in the project since the commercial launch of TFC-1067.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For further information: Investor Enquiries: Jonathan Williams, Managing Director, Momentum PR, Canada, Phone: 1.450.332.6939, Email: firstname.lastname@example.org; Corporate Enquiries: Dr. Howard Verrico, CEO, Chairman of the Board, Sirona Biochem Corp., Phone: 1.604.641.4466, Email: email@example.com